Share This Page
Drugs in ATC Class P
✉ Email this page to a colleague
Subclasses in ATC: P - Antiparasitic products, insecticides and repellents
P Market Analysis and Financial Projection
The ATC Class P (Antiparasitic products, insecticides, and repellents) market is experiencing robust growth driven by rising global health threats, innovation in formulations, and evolving patent strategies. Below is a detailed analysis of market dynamics and patent trends shaping this sector.
Market Dynamics
Current Market Size and Growth Projections
- The global antiparasitic drugs market was valued at $17.9 billion in 2023 and is projected to grow at a CAGR of 5.06% to reach $25.4 billion by 2030 [18]. Alternative estimates suggest a higher CAGR of 6.9%, potentially reaching $33.99 billion by 2030, driven by vector-borne disease outbreaks and climate change [16][19].
- Insect repellent active ingredients, a subset of ATC Class P, are forecast to grow from $1.0 billion in 2023 to $1.5 billion by 2028 (CAGR: 7.6%) [10].
Key Growth Drivers
- Rising Parasitic Infections: Over 600 million people are affected by parasitic worms (e.g., Strongyloides stercoralis), with malaria and dengue cases surging globally [16][17].
- Climate Change: Warmer temperatures expand insect habitats, increasing demand for repellents and insecticides [10].
- Technological Advances:
- Combination therapies (e.g., macrocyclic lactones + neo-nicotinoids) to combat resistance [4][11].
- Natural/organic formulations gaining traction due to safety concerns [2][10].
- E-commerce Expansion: Direct-to-consumer models and telemedicine partnerships enhance accessibility [2][10].
Challenges
- Drug Resistance: Parasites like malaria-causing Plasmodium are developing resistance to standard treatments [16].
- Regulatory Hurdles: Stringent approval processes for new chemical entities delay market entry [11].
Patent Landscape
Key Trends
- Combination Therapies:
- Patents like US7368435 and US7345092 protect topical insecticides combining macrocyclic lactones, neo-nicotinoids, and insect growth regulators for enhanced efficacy [4].
- Fixed-dose combinations (FDCs) dominate non-NME approvals, reducing treatment complexity [11].
- Natural and Nanoparticle Innovations:
- US20190160016A1 covers nanoparticle-based β-triketones for lice control [13].
- Plant-derived compounds (e.g., terpineol, eugenol) are replacing synthetic chemicals [5].
- Non-Pesticide Solutions:
- Calcined kaolins (US6027740) and microbial agents target pests without chemicals [9].
Geographic and Sectoral Focus
- Asia Pacific leads in repellent patents due to dengue/malaria prevalence [10].
- Veterinary Applications: 40% of recent patents target pet treatments, reflecting demand for safer ectoparasiticides [4][5].
Regional Insights
| Region | Market Share (2023) | Growth Drivers |
|---|---|---|
| North America | 36.8% [16] | High healthcare spending, advanced R&D. |
| Asia Pacific | Fastest CAGR [19] | Climate-driven vector proliferation, urbanization. |
| Europe | Steady Growth | Emphasis on eco-friendly repellents [10]. |
Key Players and Strategies
- Top Companies: Merck, Novartis, Bayer, GSK, and Zoetis [16][19].
- Strategies:
- R&D Partnerships: AbbVie and Summit VetPharm collaborate on veterinary formulations [4].
- Acquisitions: Expansion into emerging markets with high disease burdens [17].
Future Outlook
- Sustainable Innovations: Biopesticides and genetic engineering (e.g., CRISPR for parasite-resistant crops) will dominate patents [9].
- Digital Integration: AI-driven pest monitoring systems paired with targeted repellent delivery [2].
"The shift toward non-chemical pest management reflects both ecological concerns and evolving regulatory landscapes." – WIPO Patent Landscape Report [9].
Key Takeaways
- ATC Class P growth hinges on combating resistance through innovation.
- Natural and combination products are patent hotspots.
- Asia Pacific remains critical for market expansion.
FAQs
Q: What defines ATC Class P?
A: It includes drugs and products targeting parasites (e.g., antiprotozoals, anthelmintics) and arthropods (insecticides, repellents) [14].
Q: How do patents impact market access?
A: Patent cliffs (e.g., AbbVie’s glecaprevir expiring in 2031) may delay generics but drive next-gen formulations [12].
Q: Which regions are most affected by parasitic diseases?
A: Sub-Saharan Africa, South Asia, and South America account for 70% of infections [16][18].
References
- https://www.marketsandmarkets.com/Market-Reports/air-traffic-control-equipment-market-159216929.html
- https://sites.google.com/view/brandpulseinsights/top-reports/north-america-anti-parasite-products-market-by-application-market-trends
- https://www.frontiersin.org/articles/10.3389/frma.2023.978249/full
- https://patents.justia.com/patents-by-us-classification/514/875
- https://patents.justia.com/patents-by-us-classification/424/DIG10
- https://www.iqvia.com/-/media/iqvia/pdfs/files/iqvia-quarterly-pharmaceutical-market-outlook---november-2023.pdf
- https://www.alliedmarketresearch.com/air-traffic-control-equipment-market
- https://github.com/deyniphytic/Market-Research-Report-List-1/blob/main/antiparasitic-drugs-market.md
- https://www.wipo.int/web-publications/patent-landscape-report-agrifood/en/4-non-pesticide-pest-and-disease-management.html
- https://www.marketsandmarkets.com/Market-Reports/insect-repellent-active-ingredients-market-111358884.html
- https://pmc.ncbi.nlm.nih.gov/articles/PMC4607470/
- https://www.treatmentactiongroup.org/wp-content/uploads/2021/11/hcv_tb_longacting_patent_trends.pdf
- https://patents.google.com/patent/US20190160016A1/en
- https://en.wikipedia.org/wiki/ATC_code_P
- https://funginstitute.berkeley.edu/wp-content/uploads/2013/12/Golden_Goose.pdf
- https://www.gminsights.com/industry-analysis/antiparasitic-drugs-market
- https://www.thebusinessresearchcompany.com/report/antiparasitic-drugs-global-market-report
- https://www.grandviewresearch.com/industry-analysis/antiparasitic-drugs-market-report
- https://www.mordorintelligence.com/industry-reports/global-antiparasitic-drugs-market
More… ↓
